Investor reaction to Vertex data too harsh?
This article was originally published in Scrip
Executive Summary
New cystic fibrosis data from Vertex Pharmaceuticals has investors discouraged, pushing the stock down almost 4% to linger near $126 at the end of trading on 23 March, despite the study showing positive results that have confirmed the company's move into Phase III.